Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Myelodysplastic Syndromes 26Lymphoma, Non-Hodgkin 20Hematologic Neoplasms 20Lymphoma 19Multiple Myeloma 18Recurrence 15Lymphoma, B-Cell 15Lymphoma, Large B-Cell, Diffuse 13Leukemia, Lymphocytic, Chronic, B-Cell 12Burkitt Lymphoma 12Breast Neoplasms 11Ovarian Neoplasms 10Lymphoma, Follicular 10Pancreatic Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Neoplasm Metastasis 8Myeloproliferative Disorders 8Melanoma 8Lymphoma, Mantle-Cell 7Lymphoma, B-Cell, Marginal Zone 7Leukemia, Biphenotypic, Acute 7Leukemia 7Hodgkin Disease 7Glioblastoma 7Carcinoma, Non-Small-Cell Lung 7Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Osteosarcoma 6

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × fludarabine × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡